Project 1 Viral Genomics: surveillance, epidemiology, host response, and viral immunogenicity

项目 1 病毒基因组学：监测、流行病学、宿主反应和病毒免疫原性

• 批准号: 10163684
• 负责人: Pardis Christine Sabeti
• 金额: $ 35万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-10 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10163684
• 关键词: 2019-nCoV; Address; Award; Biological Assay; Boston; COVID-19; Cessation of life; China; Chiroptera; Cities; Clinical; Clustered Regularly Interspaced Short Palindromic Repeats; Communities; Complement; Coronavirus; Data; Devices; Diagnostic; Discriminant Analysis; Discrimination; Disease Outbreaks; Disease Surveillance; Epidemiology; Etiology; Evaluation; Evolution; Genome; Genomic Centers for Infectious Diseases; Genomics; Glare; Goals; Human; Hybrids; Immune response; Individual; Influenza; Internet; Laboratories; Libraries; Lighting; Location; Logistic Regressions; Lung diseases; Measures; Metagenomics; Methods; Monitor; Mutation; Names; National Institute of Allergy and Infectious Disease; Oligonucleotides; Pathogenicity; Pneumonia; Population; Process; Province; Public Health; Reporting; Resources; Running; Sampling; Screening procedure; Seafood; Sensitivity and Specificity; Severe Acute Respiratory Syndrome; Signal Transduction; Site; Specimen; Sum; Technology; Testing; Time; United States; Variant; Viral; Viral Genome; Virus; Work; base; clinical diagnostics; communicable disease diagnosis; computational pipelines; convolutional neural network; cost; data sharing; design; diagnostic assay; genome sequencing; human coronavirus; immunogenicity; improved; insight; interest; iterative design; meetings; metagenome; mobile computing; novel; parallelization; pathogen; point of care; prototype; respiratory; response; tool; viral genomics; whole genome

This proposal is intended to develop novel clinical diagnostics for, and increase our understanding of, the diversity, evolution, and spread of the newly emerged SARS-related coronavirus 2 (SARS-CoV-2) and other respiratory disease-causing pathogens in the United States. Coronavirus Disease 2019 (COVID-19) is associated with mild to severe respiratory disease, which can be fatal. The novel viral etiological agent was first identified in December 2019 in Wuhan City, Hubei Province, China following an outbreak of pneumonia in individuals associated with a seafood market, and has since spread globally. Originally named “2019 novel coronavirus”, the virus has since been renamed severe acute respiratory syndrome-related coronavirus (SARS-CoV-2). As of 10 February 2020, this includes 40,554 confirmed cases and 910 deaths within 25 countries1. There have been 12 confirmed cases of COVID-19 in the United States2, one of which was identified in Boston, MA in an individual who recently returned from China3. As public health agencies continue to monitor, track, and attempt to control its spread, it is most crucial that they are equipped with the most effective tools to detect SARS-CoV-2 and distinguish it from other common causes of similar respiratory illness. This proposal addresses the critical gap in clinical diagnostics amidst the quickly moving COVID-19 outbreak by advancing multiplexed and point of care tools for screening a large number of respiratory disease samples in a public health lab setting. It builds upon the genomic disease surveillance aims of the Viral project within our existing Genomic Centers for Infectious Disease (NIAID), but accounts for the increased costs based on the scale of work related to outbreak response. The tools generated by this project specifically address a glaring need at the public health laboratory level and have the potential to accelerate their investigative abilities for undiagnosed respiratory disease.

该建议旨在为我们开发新颖的临床诊断，并提高我们对 新出现的与SARS相关的冠状病毒2（SARS-COV-2）和其他的多样性，进化和传播 在美国，引起呼吸道疾病的病原体。 2019年冠状病毒病（COVID-19）与轻度至重度呼吸道疾病有关，这可以是 致命的。新颖的病毒病因学剂于2019年12月在湖北省的武汉市首次确定 与海鲜市场相关的个体肺炎爆发后中国，此后 在全球范围内传播。该病毒最初被称为“ 2019年小说冠状病毒”，此后已重命名为严重的急性 呼吸道综合征相关的冠状病毒（SARS-COV-2）。截至2020年2月10日，其中包括40,554 确认的案件和25个国家内的910例死亡。有12例证实的COVID案件 美国2，其中之一是在马萨诸塞州波士顿确定的，他最近从 中国3。随着公共卫生机构继续监视，跟踪和试图控制其传播，这是最关键的 他们配备了最有效的工具来检测SARS-COV-2并将其区分开 类似呼吸道疾病的常见原因。 该提案解决了临床诊断的关键差距，在迅速移动的Covid-19爆发中 通过推进筛查大量呼吸系统疾病样本的多路复用和护理工具 在公共卫生实验室环境中。它建立在病毒项目的基因组疾病监测目的基于 我们现有的传染病基因组中心（NIAID），但根据 与爆发反应有关的工作规模。该项目生成的工具专门解决 在公共卫生实验室一级需要巨大的需求，并有可能加速其调查能力 用于未持续的呼吸道疾病。